Data updated: Mar 10, 2026
INCIVEK
TELAPREVIR
Approved 2011-05-23
2
Indications
--
Phase 3 Trials
1
Priority Reviews
14
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2011-05-23
- Routes
- ORAL
- Dosage Forms
- TABLET
INCIVEK Approval History
Loading approval history...
What INCIVEK Treats
2 FDA approvalsOriginally approved for its first indication in 2011 . Covers 2 distinct patient populations.
- Other (2)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
INCIVEK FDA Label Details
ProINCIVEK Patents & Exclusivity
Latest Patent: May 2028
Patents (1 active)
US8431615
Expires May 30, 2028
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.